A better clot-buster drug for strokes?

April 26, 2018 by Steven Reinberg, Healthday Reporter

(HealthDay)—After a stroke, many patients are given the clot-busting intravenous drug alteplase, but another drug may be more effective, Australian researchers report.

Among more than 200 , TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.

"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients," said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville. "It is likely to change stroke treatment guidelines and clinical practice."

Campbell said tenecteplase is more effective than alteplase because of differences in the enzymes in each .

Although both drugs work in the same way, tenecteplase is better at attacking and dissolving clots, and more resistant to factors that inhibit the breakdown of clots, he said.

For either drug to be most effective, it needs to be given as soon as possible after a stroke occurs. In this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.

Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of at Long Island Jewish Hospital in Forest Hills, N.Y.

In 2000, the U.S. Food and Drug Administration approved tenecteplase for use after a , Arora said.

"Tenecteplase is being widely used in developing countries, such as India," he said. "One reason is it's cheaper than alteplase."

In the United States, tenecteplase costs about $5,800, versus alteplase, which costs $8,000, Arora said.

In addition, tenecteplase is easier to give, requiring only a single injection, while alteplase requires an injection and an IV drip, he added.

Arora explained that tenecteplase is not widely used in the United States for because these patients are typically treated with angioplasty or heart bypass surgery.

For the new study, which did not receive drug company funding, Campbell and his colleagues randomly assigned 202 to either alteplase or tenecteplase before surgery to remove clots.

The researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.

The investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of return to the brain, compared with 10 percent of those treated with alteplase.

Patients treated with tenecteplase also had better functional outcomes after 90 days than those given alteplase, the findings showed.

Bleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of , regardless of which drug they received, Campbell said.

The report was published April 26 in the New England Journal of Medicine.

Explore further: New drug treatment could offer stroke survivors better outcomes

More information: Bruce Campbell, MBBS, Ph.D., head, stroke department, Royal Melbourne Hospital, Parkville, Australia; Rohan Arora, MBBS, director, stroke, Long Island Jewish Hospital, Forest Hills, New York; April 26, 2018, New England Journal of Medicine.

For more on stroke, visit the National Stroke Association.

Related Stories

New drug treatment could offer stroke survivors better outcomes

February 26, 2015
Promising results for a new drug treatment for ischaemic stroke patients have been published today in the journal Lancet Neurology.

Tenecteplase drug bests standard treatment for certain strokes

March 22, 2012
(HealthDay) -- A medication called tenecteplase may be more effective at treating strokes caused by clots in large blood vessels in the brain than the current standard therapy, Australian researchers report.

Ischemic stroke patients not receiving life-saving treatment, study finds

October 5, 2017
Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers at Georgia State University.

Benefits / risks for fibrinolytic therapy in intermediate-risk PE

April 11, 2014
(HealthDay)—A single intravenous bolus of tenecteplase reduces early death and hemodynamic decompensation in normotensive patients with intermediate-risk pulmonary embolism, but increases the risk of major hemorrhage and ...

Low-dose alteplase no better for acute ischemic stroke

October 3, 2017
(HealthDay)—For key demographic subgroups of patients with acute ischemic stroke (AIS), low-dose alteplase does not differ from standard-dose alteplase in terms of treatment effects on death or disability, according to ...

Brain scan study shows clot-busting drug benefits stroke patients

April 9, 2015
A drug that breaks up blood clots in the brains of stroke patients could be used more widely than at present without increased risk, a brain scan study suggests.

Recommended for you

Physical activity necessary to maintain heart-healthy lifestyle

September 24, 2018
Exercise and physical activity are of vast global importance to prevent and control the increasing problem of heart disease and stroke, according to a review paper published today in the Journal of the American College of ...

Height may be risk factor for varicose veins, study finds

September 24, 2018
The taller you are, the more likely you are to develop varicose veins, according to a study led by Stanford University School of Medicine researchers that examined the genes of more than 400,000 people in search of clues ...

Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death

September 24, 2018
In the largest multi-institutional study to date, led by researchers from Penn Medicine, the team found that among patients who underwent a transcatheter aortic valve replacement (TAVR), a high number experienced severe and ...

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Can a common heart condition cause sudden death?

September 20, 2018
About one person out of 500 has a heart condition known as hypertrophic cardiomyopathy (HCM). This condition causes thickening of the heart muscle and results in defects in the heart's electrical system. Under conditions ...

New drugs could reduce risk of heart disease when added to statins

September 20, 2018
New drugs that lower levels of triglycerides (a type of fat) in blood could further reduce the risk of heart attack when added to statins. These new drugs, which are in various stages of development, could also reduce blood ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.